Patent ID: 9545450
Date: 2017-01-17
CPC Classifications: A61K,A61P,C07K,C12N

Claim:
1. A method of making a targeting peptide conjugated to a recombinant lysosomal enzyme, the method comprising: conjugating a first crosslinking agent modified recombinant human lysosomal enzyme to one or more second crosslinking agent modified variant IGF-2 peptides, wherein the first crosslinking agent modified recombinant lysosomal enzyme comprises a recombinant lysosomal enzyme characterized as having a chemically modified N-terminus and one or more modified lysine residues; and the one or more second cross linking agent modified variant IGF-2 peptides comprise one or more variant IGF-2 peptides comprising a modified amino acid within a short extension linker at the amino (N)-terminus, wherein the lysosomal enzyme is selected from the group consisting of human acid α-glucosidase, human acid αgalactosidase A, human acid β-glucuronidase, human acid α-iduronidase A, human acid iduronidate 2-sulfatase, human β-hexosaminidase A, human β-hexosaminidase B, human acid α-mannosidase A, human β-glucocerebrosidase, human acid lipase, and any combinations thereof, and the one or more variant IGF-2 peptides comprising SEQ ID NO: 2 with one or more of the following modifications with respect to the amino acid sequence of SEQ ID NO:2: